- Home
- TTNP vs AZTR Comparison
TTNP vs AZTR Comparison
Compare TTNP & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- AZTR
- Stock Information
- Founded
- TTNP 1991
- AZTR 2014
- Country
- TTNP United States
- AZTR United States
- Employees
- TTNP N/A
- AZTR N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- AZTR Health Care
- Exchange
- TTNP Nasdaq
- AZTR Nasdaq
- Market Cap
- TTNP 3.0M
- AZTR 3.2M
- IPO Year
- TTNP 1996
- AZTR 2023
- Fundamental
- Price
- TTNP $3.79
- AZTR $0.25
- Analyst Decision
- TTNP
- AZTR
- Analyst Count
- TTNP 0
- AZTR 0
- Target Price
- TTNP N/A
- AZTR N/A
- AVG Volume (30 Days)
- TTNP 41.9K
- AZTR 3.0M
- Earning Date
- TTNP 01-03-2025
- AZTR 03-14-2025
- Dividend Yield
- TTNP N/A
- AZTR N/A
- EPS Growth
- TTNP N/A
- AZTR N/A
- EPS
- TTNP N/A
- AZTR N/A
- Revenue
- TTNP N/A
- AZTR $97,500.00
- Revenue This Year
- TTNP N/A
- AZTR N/A
- Revenue Next Year
- TTNP N/A
- AZTR N/A
- P/E Ratio
- TTNP N/A
- AZTR N/A
- Revenue Growth
- TTNP N/A
- AZTR N/A
- 52 Week Low
- TTNP $3.03
- AZTR $0.24
- 52 Week High
- TTNP $14.80
- AZTR $68.40
- Technical
- Relative Strength Index (RSI)
- TTNP 48.54
- AZTR 36.62
- Support Level
- TTNP $3.14
- AZTR $0.24
- Resistance Level
- TTNP $3.38
- AZTR $0.65
- Average True Range (ATR)
- TTNP 0.22
- AZTR 0.06
- MACD
- TTNP 0.02
- AZTR -0.02
- Stochastic Oscillator
- TTNP 52.24
- AZTR 1.71
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.